nalbuphine HCl ER
Phase 2/3Completed 0 watching 0 views this week📈 Rising
60
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prurigo Nodularis
Conditions
Prurigo Nodularis, Nodularis Prurigo, Prurigo
Trial Timeline
Aug 15, 2015 → Sep 3, 2017
NCT ID
NCT02174432About nalbuphine HCl ER
nalbuphine HCl ER is a phase 2/3 stage product being developed by Trevi Therapeutics for Prurigo Nodularis. The current trial status is completed. This product is registered under clinical trial identifier NCT02174432. Target conditions include Prurigo Nodularis, Nodularis Prurigo, Prurigo.
Hype Score Breakdown
Clinical
22
Activity
15
Company
5
Novelty
7
Community
8
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02174432 | Phase 2/3 | Completed |
| NCT02143973 | Phase 2/3 | Completed |
| NCT02373215 | Phase 1 | Completed |
Competing Products
20 competing products in Prurigo Nodularis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Vixarelimab + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| Upadacitinib | AbbVie | Approved | 85 |
| Pimecrolimus + Hydrocortisone + Pimecrolimus | Novartis | Phase 2 | 52 |
| Rocatinlimab + Placebo | Amgen | Phase 3 | 76 |
| Abrocitinib | Pfizer | Phase 2 | 51 |
| Dupilumab SAR231893 (REGN668) | Sanofi | Pre-clinical | 22 |
| Dupilumab | Sanofi | Phase 3 | 76 |
| Dupilumab | Sanofi | Pre-clinical | 22 |
| Dupilumab | Sanofi | Pre-clinical | 22 |
| Ruxolitinib Cream 1.5% | Incyte | Phase 1 | 30 |
| Ruxolitinib Cream + Vehicle Cream | Incyte | Phase 3 | 74 |
| INCB054707 + Placebo | Incyte | Phase 2 | 49 |
| Povorcitinib + Placebo | Incyte | Phase 3 | 74 |
| Povorcitinib + Placebo | Incyte | Phase 3 | 74 |
| Ruxolitinib Cream + Vehicle Cream | Incyte | Phase 3 | 74 |
| CDX-0159 + Normal saline | Celldex Therapeutics | Phase 1 | 28 |
| barzolvolimab | Celldex Therapeutics | Phase 2 | 47 |
| nalbuphine HCl ER tablets 90 mg BID + nalbuphine HCl ER tablets 180 mg BID + Placebo tablets BID | Trevi Therapeutics | Phase 2/3 | 60 |
| Nalbuphine ER Tablets + Placebo Tablets | Trevi Therapeutics | Phase 2/3 | 60 |
| serlopitant + Placebo | Vyne Therapeutics | Phase 2 | 44 |
Other Products from Trevi Therapeutics
nalbuphine HCl ER tablets 90 mg BID + nalbuphine HCl ER tablets 180 mg BID + Placebo tablets BIDPhase 2/3
60
nalbuphine HCl ERPhase 2/3
60
nalbuphine HCl ER tablets 60 mg BID + nalbuphine HCl ER tablets 120mg BID + Placebo tablets BIDPhase 2/3
60
Nalbuphine ER Tablets + Placebo TabletsPhase 2/3
60
NAL ER + Placebo + NAL ER + NAL ERPhase 2
47